Objective: To evaluate efficacy, safety, and midterm patency of endovascular treatment of obstructive popliteal artery (PA) disease.
Endovascular interventions for femoropopliteal lesions of claudication and critical limb ischemia (CLI) have been widely used in the past decade. [1] [2] [3] Recently, advances in endovascular techniques have led to a more aggressive approach to the treatment peripheral artery disease (PAD). In fact, they have been considered by many centers as the first-line therapeutic modality for patients with complicated cases, including femoropopliteal chronic total occlusions (CTOs) and TransAtlantic Inter-Society Consensus II classification C and D lesions. [4] [5] [6] The latest data from studies on nitinol stent placement in long femoropopliteal lesions have indicated encouraging primary patency rates of 70% to 80% at 12 months. 7, 8 Despite the positive results of endovascular interventions for femoropopliteal lesions, limited data are available on isolated popliteal artery (PA) obstructive diseases. The PA, unlike the superficial femoral artery, presents unique characteristics, including extreme mobility between the proximal and distal fixation points and the biomechanical forces resulting from repetitive motion. 9 Thus, the PA is traditionally considered a no-stent zone, and stent placement is only reserved for suboptimal results after percutaneous transluminal angioplasty (PTA), such as significant recoil, flowlimiting dissection, or significant residual stenosis. 10 The purpose of this study was to evaluate the clinical outcomes with the use of the nitinol stent in the management of isolated PA lesions in patients with PAD. To derive morphologic changes of the PA during knee flexion, dynamic angiography (knee flexion at 90 ) was performed in all the patients. The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.
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METHODS
Study group. Institutional review board approval was obtained for this study. The study comprised a retrospective review of a prospectively maintained database of Shanghai Ninth People's Hospital from June 2011 through June 2014. Forty-three consecutive patients with PAD and PA obstructive lesions who had undergone endovascular treatment were identified. Those patients considered poor surgical candidates based on (1) lack of suitable autogenous conduit for distal bypass (n ¼ 9); (2) absence of good distal bypass target vessels (n ¼ 10); (3) elderly patients with multiple comorbidities such as congestive heart failure, symptomatic coronary artery disease, myocardial infraction, or stroke that would make them high risk for general anesthesia (n ¼ 21); and (4) limited life expectancy such as end-stage cancer (n ¼ 3). The exclusion criteria included simultaneous upstream (femoral and/or iliac artery) associated procedure, acute limb ischemia, severe renal insufficiency (glomerular filtration rate <30 mL/min), contraindication to contrast media, and endovascular intervention for aneurysm, compression, or traumatic injury of the PA. Before treatment, all the patients were evaluated by using the ankle-brachial index (ABI), duplex ultrasound (DUS), and computed tomography-angiography to define the severity of ischemia and the location of lesions and to plan the revascularization strategy.
Treatment. All endovascular procedures were performed in the interventional angiography suite by experienced vascular surgeons, using the Innova 3100IQ angiography system (General Electric Company, Fairfield, Conn). Access was obtained through a 6F sheath via the ipsilateral femoral approach in most of the patients or the contralateral femoral approach in obese patients. The patient was fully heparinized to maintain an activated coagulation time of >250 seconds after sheath insertion. Intraluminal recanalization was attempted primarily with conversion to the subintimal approach if this failed. The above-knee lesions were primarily recanalized with a 0.035-in hydrophilic guide wire (Terumo Medical Corporation, Somerset, NJ) and a 4F or 5F support catheter. Hydrophilic 0.018-or 0.014-in guide wires (Boston Scientific Corporation, Natick, Mass), and matching support catheters were used typically to cross the belowknee lesions. Distal retrograde access and subintimal arterial flossing with antegrade-retrograde intervention were used in cases of failed reentry in the optimal true lumen or failed passage to the lesions. Once lesions were crossed, PTA (ClearStream Technologies Ltd, Wexford, Ireland) was subsequently performed with 3-to 6-mmdiameter balloons, same size depending on the reference artery. Balloon inflation times varied from 120 to 180 seconds at 8 to 14 atm.
Conventional angiography (anteroposterior view with knee extension) and dynamic angiography (single lateral view with knee flexion at 90 ) were performed after PTA.
The dynamic angiography allowed us to (1) detect the significant obstruction that was not visible on conventional angiography (Fig 1) ; (2) identify the further aggravated obstructions, with less than 30% residual stenosis/recoil on conventional angiography (Fig 1) ; and (3) detect morphology changes of the PA because of the presence of a stent (Fig 2) . Stents were placed in cases of flow-limiting dissection and/or more than 30% residual stenosis/recoil in either conventional or dynamic angiography. Three types of self-expanding nitinol stents were used in the present study, including Protégé Everflex (ev3 Inc, Plymouth, Minn) and LifeStent (Bard Peripheral Vascular Inc, Tempe, Ariz) for the P1 and P2 segments, and Xpert (Abbott Vascular, St. Paul, Minn) for the P3 segment. The choice of nitinol stents was based on the operator's preference, and the diameters were typically oversized by approximately 10% compared with the normal reference vessel. The results were confirmed by both using conventional and dynamic angiographies. At least one run-off vessel to the foot would be preserved with or without additional endovascular intervention. All patients provided written informed consent before treatment. The ABI was evaluated before discharge. After the operation, all patients received dual antiplatelet therapy with aspirin and clopidogrel for at least 4 weeks, with aspirin continued indefinitely.
Definitions. Lesions were assigned to the PA segments, which were defined as follows: the first popliteal segment (P1), extending from the adductor hiatus to the superior border of the femoral condyle; the second popliteal segment (P2), extending from the superior border of the femoral condyle to the joint line; and the third popliteal segment (P3), extending from the joint line to the bifurcation of the anterior tibial artery and tibioperoneal trunk. Technical success was defined as recanalization of the PA lesions with residual stenosis of <30% on both conventional and dynamic angiographies.
Follow-up. Patient demographic characteristics, interventional detail, technical success rates, and complications were recorded. Potential risk factors such as symptoms, CTO, lesion length, number of runoff artery, location of the stent, and stent fracture were also included. Follow-up visits and DUS were scheduled at 1, 3, and 6 months, and then at 3-to 6-month intervals thereafter. Significant stenosis on DUS was defined as a ratio >2.5 (peak systolic velocity at the lesion/peak systolic velocity proximal to the lesion). Patients with hemodynamic evidence of restenosis or reocclusion based on DUS underwent repeat endovascular intervention. Data on cumulative patency, limb salvage, and amputation-free survival rates were obtained from office databases and telephone contacts.
Statistical analysis. Individual data were summarized by using frequencies or percentages for categoric factors, and median (range) values for continuous variables. SPSS v 13.0 (SPSS, Inc, Chicago, Ill) was used in the statistical analyses. Cumulative patency, limb salvage, and amputation-free survival rates were calculated by using Kaplan-Meier estimates. The risk factors of primary patency loss were evaluated by using univariate and multivariate analyses with the Cox proportional hazards regression model. A P value of <.05 was considered significant.
RESULTS
This retrospective study comprised 43 limbs (23 left sides) of 43 patients (29 males) who underwent endotreatment for their obstructive PA lesions. Patient demographics and lesion information are listed in Tables I and  II , respectively. The median age was 76 years (range, 65-84 years). Thirty-six cases (83.7%) had a history of hypertension. Almost one-half of the cases had hyperlipidemia and/or diabetes mellitus (48.8% and 46.5%, respectively). Thirty patients had CLI with rest pain (44.2%) or ulcers (25.6%). CTO was present in 31 cases (72.1%). The median obstructive lesion length was 5 cm (range, 4-16 cm). Most frequently (60.5%, n ¼ 26), the second popliteal segment (P2) was involved in the target lesion (Table II) .
Technical success was achieved in 42 (97.7%) of 43 limbs. Intentional subintimal angioplasty was used in 16 (38.1%) of 43 cases, with four patients (9.5%) requiring additional retrograde subintimal recanalization. One technical failure case, caused by unsuccessful reentry of the distal true lumen, was treated conservatively, which resulted in successful limb salvage. Twenty-nine patients (69.0%) required adjunctive stents, including 20 cases (47.6%) after PTA based on conventional angiography; nine cases (21.4%) after PTA based on dynamic angiography, without significant obstruction on conventional angiography; and two cases (4.8%) because of the presence of stent, based on dynamic angiography (Fig 3) . The stent(s) landed in the P1 segment in 15 patients (35.7%), in the P2 segment in 21 patients (50.0%), and in the P3 segment in 10 patients (23.8%). Additional tibial/ peroneal PTA was performed in 10 patients (23.8%) to ensure at least one patent runoff vessel to the foot (Table III) .
Intraoperative complications occurred in two patients, including vessel perforation in one patient (2.3%) and embolism in the other (2.3%). Vessel perforation was resolved with temporary balloon occlusion, and embolism was successfully removed by performing catheter thrombus aspiration with a 6F guiding catheter. Postoperative (<7 days) myocardial infarction occurred in one patient (2.3%), groin hematoma in two patients (4.7%), and access pseudoaneurysm in one patient (2.3%), which required open repair. No perioperative amputation or death occurred (Table III) .
The mean follow-up was 18.3 months (median, 18 months; range, 6-36 months) in 42 patients with technically successful treatment. Thirty-nine patients (92.9%) were successfully followed up, whereas two patients died of nontreatment-related causes and one patient was lost to follow-up. The ABI before hospital discharge significantly improved after the intervention (from 0.92 6 0.14 to 0.49 6 0.11; P < .01). The mean Rutherford-Becker class decreased from 3.95 6 0.76 before the index stent implantation procedure to 1.81 6 1.09 at 6 months and 1.76 6 0.95 at 12 months (Table IV) . The primary, primary-assisted, and secondary patency rates at 12 months were 75.2% 6 6.8%, 82.4% 6 6.0%, and 89.9% 6 4.8%, respectively (Fig 4) . PA restenosis/occlusion occurred in 10 patients (23.8%), including four restenosis and six occlusion cases. All patients with restenosis/occlusion received re-angioplasty, which was successful in nine patients and met with technical failure in one patient, who underwent amputation 2 weeks after the failed intervention. The limb salvage and amputation-free survival rates at 12 months were 94.6% 6 3.7% and 92.1% 6 4.4%, respectively. Stent fracture occurred in three patients (7.1%). The fractures were classified as type 1 in two cases and type 2 in one case. The presence of a P3 stent (hazard ratio, 5.62; 95% confidence interval, 1.20-26.37; P ¼ .029) and long lesion length ($10 cm; hazard ratio, 5.35; 95% confidence interval, 1.18-24.2, P ¼ .029) were found to be significant risk factors of primary patency loss in the univariate analysis. No variables were found to be significant in the multivariate analysis (Table V) .
DISCUSSION
Endovascular treatment of severely symptomatic PA atherosclerotic lesions is a safe and effective therapy, according to the results of the present study. Our primary and secondary patency rates coincide with the outcomes of the limited reports that exclusively address endovascular intervention for PA atherosclerosis. 10 13 Moreover, the result of this special nitinol stent was investigated in another retrospective analysis by León et al, 15 which included more patients with CLI (73.5%) and longer stented length (12 cm). The primary, primary-assisted, and secondary patency rates on DUS imaging were 79.2%, 88.1%, and 93%, respectively. In the present study, the data showed comparable results in the endovascular treatment of PA lesions, with a 1-year primary patency rate of 75.2% and a secondary patency rate of 89.9%. Placement of stents in the PA is not generally accepted mostly because of the serious concern about stent fracture with exposure to high mechanical forces, significant bending, and foreshortening during knee movements. [16] [17] [18] A high incidence of stent fracture was reported by Chang et al, 18 with 50% (9/18) stent fracture rate in patients who had undergone stent placement in PA (P2 and P3) during 3-6 months of follow-up. However, only SMART Control nitinol stents (Cordis J&J medical, Miami, Fla) were used in that study. Fracture rates are markedly decreased with the extensive use of new-generation nitinol stents in the past decade. 19 The overall stent fracture rate was 3.4% in the Endovascular Treatment of Atherosclerotic Popliteal Artery Lesion-Balloon Angioplasty vs Primary Stenting trial and 7.1% in the present trial, both using new-generation nitinol stents. 11 Despite the slightly higher fracture rate, no obvious correlation was found between stent fracture and primary patency loss in our study. Moreover, with regard to the results of former reports, the relationship between stent fractures and restenosis/occlusion still could not be concluded until now. 17, 19, 20 The significant biomechanical forces of PA during knee flexion were confirmed in former studies, mainly including axial compression, bending, and twist. 19, [21] [22] [23] Furthermore, changes will become more obvious with the increase in the severity of vessel calcification. 19, 22 Dynamic angiography was recommended more than 20 years ago and might be useful in speculating the biomechanical forces during knee flexion. 24 However, in the real world, it is not so common in the endovascular treatment of PA. In the present study, compared with 
Stent placement according to the dynamic angiography (n ¼ 16)
Number of vessel runoffs (n ¼ 42) conventional angiography, dynamic angiography detected significant morphologic changes ($30% residual stenosis/recoil) in 11 cases, including nine cases after PTA and two cases after stent placement. The same phenomenon was reported in the former study. Tamashiro et al 25 found that undesired and unexpected artery obstruction occurred during knee flexion in some of the patients with atherosclerosis. Furthermore, the morphology of the PA may be altered by the presence of a stent. 19, 22 Aggressive stent placements were performed in the 11 cases with morphology changes caused by knee flexion. However, whether the method can improve the long-term patency rate of PA could not be answered yet. The 1-year primary patency rate in our study is satisfactory, even with the patients with severe diseases (69.8% CLI and 72.1% CTO). Surgical vein bypass remains the standard treatment of symptomatic PA atherosclerotic patients, with 5-year primary patency rates of 63% to 75%. 26 However, not all patients are candidates for bypass because of the lack of a conduit, limited life expectancy, and unacceptable surgical risk, just as most of the patients in the present study. Furthermore, nearly 70% of the patients had severe ischemia. According to a recent report on the prognosis of patients with CLI without treatment, the 12-month mortality and major amputation rates were 22% and 22%, respectively. 27 Comparatively, in our study, the limb salvage and amputation-free survival rates were greatly improved after endovascular treatment of PA. With consideration of stent fracture and the potential fracture-related restenosis/occlusion, patients with CLI who are not surgical candidates may get more benefits from endovascular treatment of PA. The limitations include the retrospective nature, small sample size from single institutions, partial combined crural artery lesions, lack of a control group, and shortterm follow-up. Nevertheless, this study contributes to the small body of literature supporting endovascular therapy in patients with CLI and PA atherosclerosis who have limited options for bypass surgery.
CONCLUSIONS
Endovascular treatment of lesions involving the PA is a safe and effective procedure with reasonable 1-year patency and limb salvage rates. Although the relationship between stent fracture and restenosis/occlusion is not clear yet, patients with CLI who have limited surgical options may get more benefits from the endovascular treatment of PA. 
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